Practical Toxicity Monitoring and Multidisciplinary Management in HER2-Positive Metastatic Breast Cancer

Dr. Rao outlines specific practical strategies for ILD monitoring, emphasizing high-resolution chest CT scans as the optimal detection method. Standard staging CTs may miss early ILD changes, making dedicated imaging protocols essential for patient safety.

Early detection at grade 1 (radiographic changes without symptoms) allows continued treatment with steroid management and temporary drug holds until resolution. This contrasts with grade 2 symptomatic disease requiring permanent discontinuation, making surveillance critical for maintaining patients on effective therapy.

She notes that PET-CT scans are not sufficiently specific for ILD detection, necessitating separate high-resolution chest imaging for comprehensive evaluation. This represents an additional monitoring requirement beyond standard staging procedures.

Dr. Kruse emphasizes the heightened vigilance required in curative-intent settings where treatment-related mortality becomes unacceptable. The goal involves early intervention before irreversible complications develop, supported by ASCO 2026 data showing that most patients with grade 1 ILD recover with appropriate management.

Monitoring protocols from clinical trials suggest chest CT evaluations as early as 6 weeks (around radiation therapy timing) followed by 12-week intervals during adjuvant treatment. This represents increased monitoring intensity compared to previous adjuvant regimens.

Multidisciplinary coordination becomes essential, particularly with radiation oncologists who may encounter patients during symptom development. Communication ensures all team members recognize potential pulmonary complications and maintain appropriate index of suspicion.

The panel discusses 4-drug antiemetic regimens' importance for proactive nausea prevention, with olanzapine particularly valuable for its multiple symptom benefits. Starting with comprehensive antiemetic coverage allows subsequent de-escalation if patients tolerate treatment well.

Fatigue management involves recognizing predictable patterns (typically 5-7 days post-infusion) and accommodating important life events through flexible scheduling. Dose reduction strategies maintain efficacy while improving tolerability for long-term therapy.